Fig. 3: Validation of the association between Notch signaling and immune gene sets and clinical benefit to immune checkpoint blockade in relapsed small cell lung cancer.

a Swimmer plot indicating response and length of time on therapy for individual patients in the Rochester validation cohort. Patients with clinical benefit (CB) are those with complete or mixed response and patients with no clinical benefit (NCB) are those with progressive or not evaluable disease. b ssGSEA Reactome immune gene set scores and c ssGSEA Hallmark Notch signaling gene set score in tumors of patients with and without clinical benefit to ICB. Each circle represents a tumor from a given patient. d Enrichment of Reactome gene sets related to Notch signaling in patients with clinical benefit to ICB. Asterisks denote significantly enriched gene sets (unadjusted p < 0.05). e ssGSEA scores of Reactome gene sets related to receptor tyrosine kinase and MET activation in tumors of patients with and without clinical benefit following ICB. Statistical significance was tested with a two-tailed Mann–Whitney U test. Boxplots represent the median, 25th and 75th percentiles and the vertical bars span the 5th to the 95th percentiles. Timing of responses are not shown for individual patients in swimmer plot. PD progressive disease, NE not evaluable disease. Source data are provided as a Source Data file.